AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune has amended its 2018 collaboration agreement with Eli Lilly to continue developing Morphomer® Tau aggregation inhibitors for Alzheimer's disease and other neurodegenerative conditions. The amendment reflects significant progress with Morphomer small molecules, adding new lead and backup candidates, and includes milestone payments totaling…